| |
| |
|
|
R E S O L U T I O N
|
|
|
WHEREAS, Cardiovascular disease is the leading cause of death |
|
|
in the United States, and approximately 21 million U.S. patients |
|
|
have been diagnosed with atherosclerotic cardiovascular disease, |
|
|
indicating that they are at risk of a cardiovascular event; and |
|
|
WHEREAS, In Texas, health care professionals have diagnosed |
|
|
angina, strokes, heart attacks, or coronary heart diseases for more |
|
|
than 1,790,000 adults, and these conditions have been identified as |
|
|
manifestations of atherosclerotic cardiovascular disease; in |
|
|
addition, over 864,000 adult Texans have reported experiencing a |
|
|
heart attack in their lifetime, and more than 798,000 have reported |
|
|
experiencing a stroke; the heart disease death rate in Texas is 328 |
|
|
deaths per 100,000 individuals over the age of 35, surpassing the |
|
|
national rate of 319.5; and |
|
|
WHEREAS, Research shows that atherosclerotic cardiovascular |
|
|
disease is linked to the buildup of cholesterol in the arteries, and |
|
|
the risk of cardiovascular events can be reduced by decreasing |
|
|
low-density lipoprotein cholesterol (LDL-C) levels; nearly 70 |
|
|
million U.S. adults had higher than recommended LDL-C levels in |
|
|
2016, and more than 43 million U.S. residents are currently being |
|
|
treated with lipid-lowering therapies to manage cardiovascular |
|
|
risk; statins are one of the leading lipid-lowering therapies, and |
|
|
20 percent of atherosclerotic cardiovascular disease patients |
|
|
taking statins have achieved healthy levels of LDL-C; and |
|
|
WHEREAS, The total direct and indirect cost of |
|
|
atherosclerotic cardiovascular disease in the U.S. was $555 billion |
|
|
in 2016, and the cost is projected to reach $1.1 trillion by 2035; |
|
|
each year, the State of Texas spends an estimated $10.53 billion on |
|
|
direct medical expenses for health care related to atherosclerotic |
|
|
cardiovascular disease; and |
|
|
WHEREAS, Cardiovascular diseases impact the lives of |
|
|
countless residents across the state, and it is vital that these |
|
|
Texans have access to quality health care; now, therefore, be it |
|
|
RESOLVED, That the House of Representatives of the 88th Texas |
|
|
Legislature hereby urge the Texas Department of State Health |
|
|
Services and the Texas Health and Human Services Commission to |
|
|
expand their comprehensive cardiovascular screening programs and |
|
|
explore ways to collaborate with federal and national agencies and |
|
|
organizations to establish or expand cardiovascular screening |
|
|
programs; and, be it further |
|
|
RESOLVED, That the Texas cardiovascular plan should be |
|
|
updated to enhance the quality of care rendered to patients and |
|
|
improve health outcomes; and, be it further |
|
|
RESOLVED, That the House of Representatives of the 88th Texas |
|
|
Legislature hereby express support for the creation of policies to |
|
|
lower the rates of death caused by atherosclerotic cardiovascular |
|
|
disease; and, be it further |
|
|
RESOLVED, That the chief clerk of the Texas House of |
|
|
Representatives forward an official copy of this resolution to the |
|
|
commissioners of the Texas Department of State Health Services and |
|
|
the Texas Health and Human Services Commission. |
| |
|
|
Raymond |
|
|
|
|
|
______________________________ |
|
|
Speaker of the House |
| |
|
|
I certify that H.R. No. 435 was adopted by the House on May |
|
|
12, 2023, by the following vote: Yeas 143, Nays 0, 2 present, not |
|
|
voting. |
|
|
|
|
|
______________________________ |
|
|
Chief Clerk of the House |
| |